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Abstract We report on a youngster followed by his
paediatrician from birth until 14 years of age for premature
beats, most likely of ventricular origin. The sudden death of
his sister provoked a re-assessment of his electrocardio-
grams (ECG), resulting in the diagnosis of Brugada
syndrome and the subsequent implantation of a cardio-
verter defibrillator. This syndrome is a well known entity in
adult cardiology, first described by Brugada and Brugada
in 1992. It is considered to be the second most common
cause of death in young adults after road traffic accidents.
In children, however, the Brugada syndrome is not well
known and we believe to be certainly underdiagnosed.
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death . Bundle branch block . Ventricular fibrillation
Abbreviations ECG: Electrocardiogram . EP study:
Electrophysiological study . ICD: Implantable cardioverter
defibrillator . RBBB: Right bundle branch block
Introduction
The Brugada syndrome, as described by Brugada and
Brugada in 1992, is a cardiac electrical disease which
includes an atypical right bundle branch block (RBBB)
pattern with ST-T segment alterations [9]. Over the last
10 years, this syndrome has received a great deal of
attention in cardiology literature, due to its association with
sudden death. Reports of Brugada syndrome in the
paediatric literature, however, remain limited to a small
number of publications [2, 20, 23, 24, 27, 30].
Although it is generally assumed to be uncommon in the
paediatric population, one should exclude the Brugada
syndrome in a child with a family history of unexplained
sudden death [30].
Case Report
Our patient was born following a normal pregnancy and
delivery in 1991. His physical examination was normal,
except for an irregular cardiac rhythm. He was referred to a
paediatric cardiologist because his electrocardiogram
(ECG) showed right-axis deviation (190°) and repetitive
monomorphic premature beats of likely ventricular origin
(Fig. 1). His echocardiogram was normal and he was
followed on a 3-month basis.
His ECG at 3 months remained abnormal, but differed
from the one at birth (Fig. 2, panel A). The ECG showed an
RBBB pattern with deep negative T-waves in the right
precordial leads. The child remained asymptomatic and
was followed regularly. A progressive reduction in the
amplitude of the RBBB was noted (Fig. 2, panel B and C).
In 2004, his previously healthy 20-year-old sister died
suddenly after a meal without any explanation on autopsy.
The brother was then referred to our Paediatric Cardiology
Unit for re-evaluation.
He had remained asymptomatic, but his baseline ECG
(Fig. 3) now showed a “coved-type” RBBB pattern with
deep negative T-waves in the right precordial leads [3].
Echocardiogram and cardiac-MRI did not show any
structural anomalies. Holter recording and stress testing did
not report any arrhythmia. Nevertheless, the intravenous
infusion of Ajmaline (a class IA sodium channel blocker) at
increasing dose enhanced the repolarisation anomalies in
leads V1 and V2, as reported in Brugada syndrome. An
electrophysiology (EP) study was then performed, which
showed inducible polymorphic ventricular tachycardia.
Because of his positive family history, spontaneous type-1
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Brugada pattern and inducibility at EP study, the patient
was considered at high risk for sudden death and underwent
implantation of an implantable cardioverter defibrillator
(ICD).
The first- and second-degree relatives of the family were
then screened (clinical evaluation and an ECG). Two
additional members (his mother and a maternal uncle) with
suggestive ECG pattern of Brugada syndrome were further
investigated (Ajmaline test) and were diagnosed with
Brugada syndrome and also implanted with an ICD. The
family underwent genetic testing, but the results are still
pending.
Discussion
This case report illustrates a typical case of Brugada
syndrome in children: an asymptomatic child with a
structurally normal heart showing pre-existent ECG
anomalies (premature beats and atypical RBBB) and
sudden unexpected death of a close relative.
The Brugada syndrome is mainly a disease of the young
adult, with a mean age at sudden death of 41±15 years, but
also includes patients as young as a few days old [22, 23,
25]. It is the second leading cause of death after road traffic
accidents in young adults [3]. However, its prevalence is
Fig. 1 ECG V1 and V2 pre-
cordial leads showing mono-
morphic premature beats
(duration 120 ms) in trigeminy
(arrows). The absence of
P-waves preceding aberrant
complexes suggests a ventric-
ular origin. However, a
supraventricular origin cannot
be excluded
Fig. 2 ECG V1 and V2 pre-
cordial leads at 3 months, 4 and
9 years old (A, B and C,
respectively) showing RBBB
pattern and ST segment anoma-
lies. Panel A: ECG at 3 months
remained abnormal, but differed
from the one at birth. The ECG
showed an RBBB pattern with
deep negative T-waves in the
right precordial leads. Panel B
and C: A progressive reduction
in the amplitude of the RBBB is
noted. However, panel C clearly
shows some slurring of the
downslope of the R′-wave (ar-
rows) and persistence of an
overt negative T-wave
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difficult to assess because of the dynamic aspect of the
ECG pattern, influenced by many parameters, but also
because of the difference in the criteria which are used to
define it. Prevalence ranges from 5 per 10,000 inhabitants
up to 70 per 10,000 inhabitants, with the highest prevalence
in south-east Asia [3, 16].
It is primarily an electrical disease involving cardiac
sodium channels, as in long QT syndrome type-3. Some
overlap between the two diseases exists. Both are
associated with mutations in the SCN5A gene, but at
different sites of the gene [7]. The SCN5A gene is coding
for the α-subunit of the cardiac sodium channel; it is the
only gene found to be linked to Brugada syndrome.
Inheritance occurs via an autosomal dominant mode of
transmission and more than 80 mutations have been
discovered, leading to many different phenotypes. Curi-
ously, a male preponderance of the ECG phenotype (8 to 10
times more prevalent) is observed, but is not yet completely
understood, although sex hormones seem to play a
significant role [11, 14, 31]. SCN5A mutations, however,
are found in only 18% to 30% of Brugada syndromes and,
thus, are of limited help for the screening, diagnosis and
management of the disease [3].
These abnormal channels have an altered function which
reduces the inward sodium current, inducing conduction
delay and enhancing susceptibility to re-entrant ventricular
arrhythmias [13]. Nevertheless, the strong assumption that
the Brugada syndrome is an electric disorder, without any
functional and structural cardiac abnormalities, has been
recently challenged by Frustaci et al. [12]. They detected
structural alterations on endomyocardial biopsy (localised
right ventricular myocarditis, some with detectable viral
genomes, right ventricular cardiomyopathy or cardiomyop-
athic changes) in all of their 18 patients with Brugada
syndrome. On this basis, they suggest that the Brugada
syndrome is not purely an electrical disease but, rather, a
common electrical manifestation of structural abnormal-
ities in the right ventricle resulting from different origins:
genetic, infectious and inflammatory. However, these
findings will need confirmation.
The conduction disorder resulting from sodium channel
alteration is responsible for the ECG patterns associated
with Brugada syndrome. Only one of these patterns is
diagnostic of Brugada syndrome, known as type 1 ECG
pattern or the “coved-type” (Fig. 3). Other types of ECG
pattern, type 2 and type 3, tend to be grouped as the
“saddle-back type”, an intermediate pattern that requires
conversion into the “coved-type” after pharmacological
challenge or confirmation by genetic analysis to be
diagnostic of Brugada syndrome [15].
Sodium channel blockers are used to unmask transient
Brugada ECG patterns or demonstrate conversion of a
“saddle-back” to a “coved-type” ECG pattern. Four of them
are currently used: Ajmaline, Fleicanide, Procainamide and
Pilsicainide [3, 29]. Cautious administration should include
haemodynamic monitoring, continuous 12-leads ECG
recording and the availability of appropriate resuscitation
equipment.
Apart from sodium-channel blockers, many other
conditions are reported to help unmask Brugada syndrome
phenotype. Some drugs (anti-arrhythmics, anti-anginal,
psychotrops), electrolyte imbalances (hyper- and hypoka-
laemia, hypercalcaemia) and febrile state are the most
common [4, 18].
A “coved-type” ECG pattern in more than one right
precordial lead (V1–V3), in the presence or absence of
sodium-channel blockers, without any clinical symptom is
not labelled Brugada syndrome but, instead, idiopathic
Brugada ECG pattern. The syndrome should be considered
only in association with the following criteria: documented
ventricular fibrillation, polymorphic ventricular tachycar-
dia, family history of sudden cardiac death at less than
45 years of age, inducibility of ventricular fibrillation with
EP study, “coved-type” ECG pattern in family members,
syncopal episodes or nocturnal agonal respiration [29].
The spectrum of clinical presentation and prognosis in
Brugada syndrome varies widely from asymptomatic
patients with normal ECG to symptomatic ones (syncope,
seizure, nocturnal agonal respiration) with “coved-type”
ECG pattern and sudden death occurring more commonly
during sleep. The most challenging task when facing
Brugada syndrome concerns the risk stratification of
sudden death in asymptomatic patients. Unfortunately,
many subjects remain asymptomatic until their fatal event.
With the second consensus conference on the Brugada
syndrome, a risk stratification scheme has been proposed
based on a set of parameters, including presence of
symptoms (aborted sudden death, syncope, seizure, noc-
turnal agonal respiration), spontaneous or drug-induced
“coved-type” ECG pattern and positive familial history of
sudden death [3]. The utility of EP study as a screening tool
has been recently challenged [19]. For those resuscitated
from sudden death or at high risk, implantation of an ICD is
currently the only proven effective therapy [8, 10].
Prevention of ventricular fibrillation occurring sponta-
neously or during EP study has been reported in certain
Fig. 3 ECG V1 and V2 pre-
cordial leads at 13 years old
showing typical aspect of a
“coved-type,” or type-1 ECG
pattern of Brugada syndrome: a
“coved-type” ST segment ele-
vation with a negative T-wave in
the right precordial leads. Note
the overt slurring (arrows) in the
downslope of the R′-wave
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cases using different drugs, such as quinidine sulphate,
cilostazol and isoproterenol, but these findings deserve
further validation before being part of the standard
management strategy for Brugada syndrome [1, 6, 21,
26, 28].
In the literature, Brugada syndrome in children was first
described in 2000 [20]. Since then, many other cases have
been described. To date, there are only three Japanese
studies reporting the prevalence and the clinical course of
Brugada syndrome in the asymptomatic paediatric popu-
lation [17, 30, 31]. Interestingly, the prevalence of
evocative ECG pattern of Brugada syndrome is much
lower than in adults. It increases with age, from 3 per
10,000 children at a mean age of 12 years to 10 per 10,000
children at a mean age of 15 years. The highly dynamic
nature of the ECG pattern is well known, but is even more
pronounced in children [5, 11, 14, 31]. However, the
Brugada syndrome could lead to death or near-miss sudden
death, even when ECG pattern is only transient. Recently,
its possible link with sudden infant death syndrome has
been shown with the case of a 19-day-old infant
resuscitated from ventricular fibrillation, without QT
prolongation nor ST segment anomaly on ECG, but with
one of the mutations in the SCN5A gene already described
in the Brugada syndrome [23].
The most difficult task lies in establishing the optimal
management of suspected and established Brugada syn-
drome in the paediatric population. To date, only Sreeram
et al. have tackled this problem [24]. When a teenager
presents a “coved-type” ECG pattern and missed sudden
death, attitude should not differ from adults with ICD
implantations. In infants and young children, further
discussion is required. ICD implantation is not benign at
this age and will be required for the rest of the patient’s life.
The diagnosis and therapeutic strategy is still more
complex when there is only a suspicion of Brugada
syndrome, for example, when an asymptomatic girl
presents a spontaneous but transient type-1 ECG pattern
without family history of sudden cardiac death or when a
boy with a family history of Brugada or near-miss sudden
death does not have a type-1 ECG pattern. For these cases,
the question remains if we should follow adult recommen-
dations or deviate. The highly dynamic nature of Brugada
syndrome ECG patterns, the risk/benefit ratio of ICD and
the weaker probability of sudden death in children must be
taken into account and requires an adaptation of these
recommendations.
Conclusion
The Brugada syndrome is a genetic cardiac disease whose
first manifestation is often sudden death, affecting other-
wise asymptomatic young adults. Even though common
manifestation of the Brugada syndrome is in the 40s,
paediatric patients might also be affected with some
uncertainty about their prognosis. Thus, paediatricians
should be aware of the existence of Brugada syndrome,
especially in the context of sudden death amongst close
relatives and in cases of unexplained syncope or aborted
sudden death. To offer adequate management and follow-
up for a child with suspected Brugada syndrome, risk
stratification and therapeutic recommendations based on
the specificity of the Brugada syndrome in children must be
established.
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